Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Hims & Hers achieved 136% YoY subscriber growth and unveiled ambitious 2030 goals. Discover how precision medicine drives ...

A post-earnings rally in Hims & Hers Health Inc. has turned co-founder and Chief Executive Officer Andrew Dudum into a weight-loss billionaire.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Shares in Hims & Hers Health soared in early-morning trading after it announced a partnership with Wegovy maker Novo Nordisk.

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

While net income remains relatively thin, the business is scaling efficientlyand doing so across a growing number of ...

Executives of Hims & Hers always knew their ability to sell a cut-rate weight loss drug could come to an end. The question was: When? Three days before the federal government signaled that ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...